Autoinflammatory & rare systemic diseases
Club Rhumatismes et Inflammation guidelines for anti-interleukin-1 therapy: 2026 update
Methodological detailsexpert literature review up to November 2025, 13 writers (6 rheumatologists, 3 internists, 4 paediatricians), reviewed by two scientific coordinators
- Expert literature review up to November 2025
- 13 writers (6 rheumatologists, 3 internists, 4 paediatricians)
- Reviewed by two scientific coordinators
Recommendations
As issued by the authors
20 sets of guidelines on pre-treatment assessment and follow-up of patients on anti-IL-1 therapy and on the course of action in bacterial or viral infections, neoplasia, haematologic abnormalities, cardiovascular conditions, intolerance, autoimmune or demyelinating conditions, hepatitis, macrophage activation syndrome, renal failure or dialysis, drug combinations, surgery, dental care, burns or trauma, pregnancy, low-weight children, vaccination, travel, Kawasaki disease, recurrent pericarditis, acute gout attacks and Schnitzler syndrome
Original publication
Club Rhumatismes et Inflammation guidelines for anti-interleukin-1 therapy: 2026 update. Joint Bone Spine. Published 11 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →